Bayer/PharmaNetics
This article was originally published in The Gray Sheet
Executive Summary
Bayer Diagnostics invests $17.4 mil. in coagulation test developer PharmaNetics through purchase of 1.45 mil. shares of common stock at $12 each, increasing its stake in PharmaNetics from 7% to 19.9%. The pact calls for expanding the firms' distribution agreement to include PharmaNetics' Theranostics line as part of Bayer's critical care offering. Bayer will acquire non-exclusive rights to market Theranostics products in the U.S. and provide administrative support. Bayer already has exclusive rights to sell the Theranostics line outside the U.S. The platform allows physicians to manage coagulation therapy by providing rapid test results on the biological effects of drugs. PharmaNetics has collaborations with Aventis, Knoll, and AstraZeneca to develop tests for compounds made by those firms. The Theranostics market is projected to grow more than 20% annually through 2009
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.